Lee's Pharm In-licenses Novel Anticoagulant from Armetheon of the US

Lee's Pharm of Hong Kong in-licensed greater China rights (plus Thailand) to tecarfarin, a novel anticoagulant being developed by Armetheon, a Milpitas, CA company. Tecarfarin, a potential alternative to the blood thinner warfarin, is starting a large 3,000 patient US Phase III trial. To gain China rights, Lee's made an upfront payment and invested in Armetheon, plus it will pay regulatory and sales milestones along with a royalty on revenues. Further details of the agreement were not disclosed. More details.... Stock Symbol: (HK: 0950) Share this with colleagues: // //